Complexa Inc., a biopharmaceutical company developing therapies to treat fibrosis and inflammation-related diseases, announced the successful completion of a Phase 1 clinical program for its lead drug candidate CXA-10, and the beginning of preparations for Phase 2 clinical trials for focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH) in 2016.
The announcement builds on a growing trend in PAH drug development that targets inflammation. Data on the cardiovascular and renal benefits obtained by administering CXA-10 to patients was recently presented at the 2015 American Society of Nephrology’s Kidney Week.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?